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wFinal Results of the Protected Superficial Femoral Artery Trial Using
the Filter Wire EZ System
Muller-Hulsbeck S, Humme TH, Schafer JP, et al. Cardiovasc Intervent
Radiol 2010;33:1120-7.
Conclusion: A distal protection device during femoral popliteal inter-
ventions reduces distal migration of debris.
Summary: The study evaluated the safety and efficacy of a single distal
protection device (Filter Wire EZ Embolic Protection System, Boston
Scientific, Mountain View, Calif) for capturing debris during superficial
femoral artery (SFA) percutaneous interventions. An additional aim was to
define the incidence of distal embolization during SFA interventions. This
was a prospective, single-center registry. The study included 30 patients
suitable for percutaneous transluminal angioplasty (PTA). Primary end
points were occurrence of distal embolization, decreased runoff, improve-
ment in ankle-brachial index (ABI), and number of filters containing emboli.
Secondary end points included procedural or device-related death and/or
clinical target lesion revascularization, device delivery, deployment success,
and incidence of embolic recovery. Procedural success was defined as30%
residual stenosis, with no worsening of distal runoff as determined by
angiography. The study enrolled 29 patients with 30 treated limbs, suitable
for PTA, between February 2007 and March 2008. Claudication was the
indication for intervention in 26 patients and critical limb ischemia in 3. One
patient underwent treatment in both legs. The average degree of stenosis
was 86% 7%, and stenosis length ranged from 8 to 88 mm. No procedural
or device-related complications occurred. Average degree of residual steno-
sis was 10 %  10%. ABI improved from 0.56  0.16 to 0.92  0.19 (P 
.05). At 1 month, there was no ultrasound-detected waist stenoses or
dissections. Microscopic debris was found in 27 of the 30 filters used.
Particle size was 1200 640 m (range, 90-2000 m). Histologic analysis
indicated debris consisted of platelets, erythrocytes, inflammatory cells,
extracellular matrix, and cholesterol. There was no correlation between
lesion morphology and type of debris.
Comment:This is a small, single-center, nonrandomized commercially
sponsored study with the first author having a consulting arrangement with
the study sponsor. The study is obviously good marketing material for the
manufacture of the FilterWire EZ System. However, assuming the author’s
observations are accurate, the study should bring some measure of concern
to all who perform catheter-based SFA interventions, because these inter-
ventions seem to be nearly uniformly associated with distal embolization.
Long-term clinical implications of these distal emboli remain to be defined,
but as someone once said, they may not be bad, but they can’t be good! The
true clinical utility of embolic protection devices in all vascular beds remains
an intriguing, and certainly a potentially profitable, avenue of research.
Pathogenesis of Acute Aortic Dissections: A Finite Element Stress
Analysis
Nathan DP, Zu C, Gorman JH 3rd, et al. Ann Thorac Surg 2011;91:
458-64.
Conclusion: Wall stress in the thoracic aorta peaks above the sinotu-
bular junction and distal to the left subclavian artery origin. Wall stress may
contribute to the pathophysiology of thoracic aortic dissection.
Summary: In most cases, type A and type B thoracic aortic dissections
originate with entry tears, respectively, above the sinotubular junction or
distal to the left subclavian artery origin. Although thoracic dissection is
influenced by many components, including aortic diameter, hypertension,
and decreases in wall strength associated with Marfan syndrome or Ehlers-
Danlos syndrome, the precise mechanistic rationale for origin of thoracic
type A and type B dissections is not understood. The authors hypothesized
that a biomechanical approach to predicting thoracic aortic walls stress may
better define the risk of thoracic aortic dissection in individual patients. They
mapped patterns of wall stress in the thoracic aorta in normal individuals,
extrapolating wall stress patterns from normal individuals to those with
potential dissection. They identified 47 patients whose thoracic aorta was
normal by electrocardiogram-gated computed tomography angiography.
The thoracic aorta was segmentally reconstructed and triangulated to create
a geometric mesh with the ABAQUS/Explicit 6.3 program (HKS Inc,
Pawtucket, RI). A systolic pressure load of 120 mm Hg was then used to
construct a finite element analysis and to predict regional thoracic aortic wall
stress. Local maximum wall stress was highest in the sinotubular junction in
the ascending aorta and distal to the origins of the supra-aortic vessels,
including the left subclavian artery, in the aortic arch. No errors of maximum
wall stress were identified in the descending thoracic aorta. A comparison of
areas of mean peak wall stress above the sinotubular junction (0.43  0.77
p
iPa), distal to the left subclavian artery origin (0.021  0.77 MPa), and in
he descending thoracic aorta (0.06  0.01 MPa) demonstrated significant
evels of wall stress by aortic region (P  .001).
Comment: The data indicate that there are peaks in wall stress in the
ormal thoracic aorta above the sinotubular junction and just distal to the
rigin of the left subclavian artery. The implication that peaks in wall stress
ay contribute to aortic dissection is a bit of “guilt by association.” Prevent-
ng thoracic aortic dissection is likely to be a multifaceted task. Diameter,
ccording to Laplace’s Law, is currently used as a noninvasive surrogate of
ortic wall stress. Surgical intervention is timed to occur before wall stress
xceeds the maximal tensile strength of the aorta, estimated at about 800
Ps. Although the risk of acute aortic events is currently correlated roughly
ith size, even small aortas can have fatal dissections and ruptures. Improv-
ng wall strength of the aorta, decreasing expansion rates, and calculations of
all sheer stress will all likely, in the future, be used in the management of
atients with thoracic and abdominal aortic disease.
esults of Single- and Two-Vessel Mesenteric Artery Stents for
hronic Mesenteric Ischemia
algor RD, Oderich GS, McKusick MA, et al. Ann Vasc Surg 2010;24:
094-101.
Conclusions: Stenting of both the celiac artery and the superior
esenteric artery (SMA) for chronic mesenteric ischemia (CMI) does not
educe recurrent symptoms or reinterventions compared with stenting of the
MA alone. Isolated celiac stenting carries a high risk of symptom recur-
ence.
Summary: Mesenteric artery stenting is gaining wider acceptance for
he treatment of CMI. It relieves symptoms of CMI in 78% to 100% and has
ower morbidity and mortality compared with open reconstruction. How-
ver, the durability of mesenteric stenting is questioned. Primary patencies
ave ranged from 30% to 82%, and 17% to 64% of patients have recurrent
ymptoms at 2 years of follow-up (Atkins MD et al [J Vasc Surg 2007;45:
162-71]; AbuRahma AF et al [J Endovasc Ther 2003;10:1046-53]). It is
enerally agreed that the SMA is the primary target vessel for revasculariza-
ion for patients with CMI. In open surgical procedures, it is debated
hether revascularization of the SMA alone is adequate treatment. In
ndovascular therapy for CMI, it is also unclear whether stenting of the
eliac artery in addition to the SMA adds to the durability treatment. The
urpose of this study was to describe the outcomes of single-vessel vs
wo-vessel mesenteric stent placement in patients with CMI secondary to
therosclerotic disease. The authors reviewed 101 patients (41 men, mean
ge 73  13 years) who were treated with mesenteric artery stents from
998 to 2008. Patients treated with single-vessel SMA stents (group A),
wo-vessel celiac artery and SMA stents (group B), and patients treated with
solated celiac artery stenting (group C), were reviewed with respect to
linical data and outcomes. The groups were analyzed for differences in
orbidity and mortality and freedom from recurrent symptoms and reinter-
ention. There were 61 patients in group A, 24 in group B, and 16 in group
. Demographics, cardiovascular risk factors, and clinical presentation were
imilar among the three groups. The three groups had similar early mortality
2%, 4%, and 0%, respectively), morbidity (18%, 26%, and 12%, respectively),
nd symptom relief (95%, 78%, and 100%, respectively). Freedom from
eintervention at 1 and 3 years was similar in group A (86% 5% and 50%
%), group B (67%  11% and 67%  11%), and group C (63%  13% and
3% 113%). Differences in freedom from restenosis were similar at 1 and 3
ears in group A (54%  7% and 44%  9%), group B (47%  12% and
9%  12%), and group C (43%  13% and 34  13%). Primary and
econdary patencies at 3 years were 57% and 96% for SMA stents and 61%
nd 87%, respectively, for celiac stents (P .05). Celiac artery stenting alone
as associated with symptom recurrence in 38% compared with recurrence
ates of 18% in patients who underwent SMA stent placement (P  .06).
wo-vessel stenting was associated with more complications (33%) com-
ared with stenting of the SMA (18%) or celiac artery (6%) alone. The higher
omplication rate was due to more interprocedural complications (residual
tenosis or dissection).
Comment: There was no added benefit to two-vessel stenting com-
ared with single-vessel stenting for treatment of CMI. Long-term results
ere similar, with nearly identical rates of restenosis, reintervention, and
ymptom recurrence. Two-vessel stenting was associated with more compli-
ations. The study was limited by its retrospective design. It is possible there
as a bias toward placement of two stents in patients withmore symptoms or
hen the anatomy of the SMA was suboptimal for stenting. It is conceivable
atients with poor collateralization between the celiac and SMA with signif-
cant gastric ischemic manifestations of CMImay benefit from stenting both
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July 2011280 Abstractsarteries. Overall, however, the data do not support a policy of routine
stenting of the celiac and SMA for treatment of CMI.
Safety of Stenting and Endarterectomy by Symptomatic Status in the
Carotid Revascularization Endarterectomy Versus Stenting Trial
(CREST)
Silver FL, Mackey A, Clark WM, et al. and the Crest Investigators. Stroke
2011;42:675-80.
Conclusion: For the primary Carotid Revascularization Endarterec-
tomy Versus Stenting Trial (CREST) end point of the composite of stroke,
death, and myocardial infarction, there are no significant differences be-
tween carotid artery stenting (CAS) and carotid endarterectomy (CEA) by
symptomatic status. Periprocedural stroke and death rates are significantly
lower for CEA in symptomatic patients. Nearly twice as many strokes
occurred in asymptomatic patients with CAS vs CEA (15 vs 8), but this did
not reach statistical significance.
Summary: This is a secondary analysis of CREST data. CREST inves-
tigated the safety and efficacy CAS vs CEA in patients with high-grade
carotid stenosis. A symptomatic patient was defined as having had appropri-
ate symptoms 180 days of randomization. The primary end point of
CRESTwas a composite of stroke, myocardial infarction, or death within the
periprocedural period or ipsilateral stroke up to 4 years. There were 1221
symptomatic and 1181 asymptomatic patients entered into CREST. For all
patients, the periprocedural aggregate of stroke, myocardial infarction, and
death did not differ between CAS and CEA (5.2% vs 4.5%; hazard ratio
[HR], 1.18; 95% confidence interval [CI], 0.82-1.68; P  .38). Rates of
stroke and death, however, were higher for CAS vs CEA (4.4% vs 2.3%; HR,
1.90; 95% CI, 1.21-2.98; P  .005). For symptomatic patients, periproce-
dural stroke and death rates were 7.0% 0.9% for CAS and 3.2% 0.7% for
CEA (HR, 1.89; 95% CI, 1.11-3.21; P  .02). For asymptomatic patients,
stroke and death rates were 2.5% 0.6% for CAS and 1.4% 0.5% for CEA
(HR, 1.88; 95% CI, 0.75-4.42; P  .15). Results were better in patients
aged 80 years vs those 80 years.
Comment: Every reasonable analysis of government-sponsored ran-
domized trials continues to indicate that CEA is superior to CAS for
treatment of patients with symptomatic carotid stenosis if the goal of the
procedure is to prevent stroke. Very significant questions remain about the
treatment of asymptomatic patients. The large majority of patients under-
going carotid intervention in the United States do so for asymptomatic
carotid stenosis. And yet, we really do not know the natural history of this
disease in the modern era with more advanced antiplatelet mediations, statin
medications, and better blood pressure control available now than was
available 20 years ago. However, these medications will only be effective if
the patients take them. What is needed is a three-arm trial in asymptomatic
patients with carotid artery stenosis: medical management alone vs medical
management combined with CEA vs medical management combined with
CAS. The anticipated number of events, the number of patients required,
and the number of centers required will likely be large for such a study.
However, given the demographics of carotid interventions in the United
States, the potential public health and economic effect of the results of such
a trial would be felt immediately.
Apolipoprotein (a) Isoforms and the Risk of Vascular Disease: A
Systematic Review of 40 Studies Involving 58,000 Participants
Erqou S, Thompson A, Angelantonio D, et al. J Am Coll Cardiol 2010;55:
2160-7.
Conclusion: Smaller apolipoprotein (a) (apo[a]) isoforms confer an
approximately twofold higher risk of ischemic stroke or coronary heart
disease than larger isoforms of apo(a).
Summary: Lipoprotein(a) (Lp[a]) is composed of a glycoprotein mol-
ecule, apo(a), and a low-density lipoprotein (LDL) particle. Apo(a) is
responsible for the properties of Lp(a). (Marcovina SM et al [Am J Cardiol
1998:82:57U-66U]; McLean JW et al [Nature 1987;330:132-7]). In-
creased circulating Lp(a) concentration is associated with increased risk of
coronary heart disease (CHD) and stroke and is independent of other
conventional risk factors for vascular disease, including total cholesterol
level. The overall additive risk of abnormalities of Lp(a) is only about
one-quarter that seen with LDL cholesterol level (JAMA 2009;302:412-
23). However, specific Lp(a) subtypes may confer higher cardiovascular risk.
If that is the case, analysis for Lp(a) subtypes may be useful in the stratifica-
tion of vascular risk. The authors postulated that Lp(a) particles associated
with smaller rather than larger apo(a) isoforms may result in higher cardio-
vascular risk. They analyzed information from 40 studies published between
January 1970 and June 2009 that reported an association between apo(a)
isoforms and the risk of ischemic stroke or CHD. This involved 11,396
patients and 46,938 controls in 36 studies that used comparable phenotyp-
ing and analytic methods to assess apo(a) isoform size. These studies yielded
a combined relative risk for CHD of 2.08 (95% confidence interval [CI],
1.67-2.58) for subjects with smaller vs larger apo(a) isoforms. There was
substantial heterogeneity among the studies (I2 85%; 95% CI, 80%-89%).
b
Meterogeneity was mainly explained by differences in analytical approaches
nd laboratory methods. Six studies of ischemic stroke used comparable
henotypic methods with a combined relative risk of 2.14 (95% CI, 1.85-
.97).
Comment: Apo(a) size heterogeneity is a function of a copy number
ariation of one protein domain, kringle IV type 2, the gene for which exists
n 5 to 50 identically repeated copies. Copy number variation of the gene
onfers marked heterogeneity in the molecular mass of the apo(a) isoform
Boffa MB [Clin Biochem 2004;37:333-43]). Apo(a) subtyping has been
linically limited because it adds a relatively modest incremental risk com-
ared with other biomarkers for cardiovascular disease. However, this study
ndicates there are subtypes of apo(a) that may be worth looking for. It will
eed to be determined whether smaller apo(a) isoforms have sufficient
elevance in determining vascular risk independent from Lp(a) concentra-
ion when compared to other more conventional risk factors for atheroscle-
osis.
arotid Artery Stenting Versus Carotid Endarterectomy: A Compre-
ensive Meta-Analysis of Short-Term and Long-Term Outcomes
conomopoulos KP, Sergentanis TN, Tsivgoulis G, et al. Stroke 2011;42:
87-92.
Conclusion: Long-term and short-term outcomes of carotid endarter-
ctomy (CEA) are both superior to those of carotid artery stenting (CAS),
ut there may be subgroups where results are more equivalent.
Summary: Before this meta-analysis, the most recent meta-analysis of
he results of CEA vs CAS was performed by Meier et al (BMJ 2010;340:
467). Since the Meier et al publication, there has subsequently been
ublication of the Carotid Revascularization Endarterectomy Versus Stent
rial (CREST), as well as publication of the long-term results of the Carotid
nd Vertebral Artery Transluminal Angioplasty Study (CAVATAS) and the
tent-Supported Percutaneous Angioplasty of the Carotid Artery Versus
ndarterectomy (SPACE) trial. This new meta-analysis was performed to
rovide short-term and long-term comparisons between CEA and CAS
sing all available data from published randomized trials. Short-term results
ere defined as 30 days. Analysis and long-term outcomes were depicted
ith hazard ratios for 1 year results.
Therewere 13 randomized trials incorporating3723CEAs and3754CAS
atients. CASwas associated with short-term elevated risk for stroke and “death
r stroke.” There was also a marginal trend towards higher death and “death or
isabling stroke” with CAS. Rates of cranial nerve injury and myocardial
nfarction were higher with CEA. With respect to long-term results, CAS was
ssociated with higher rates of stroke (pooled odds ratio, 1.37; 95% confidence
nterval, 1.13-1.65) and higher rates of “death or stroke” (pooled odds ratio,
.25; 95% confidence interval, 1.06-1.48). Results were replicated with pooled
azard ratios. The difference in long-term stroke rates was most apparent in
atients aged68 years, with little differences observed in rates in patients aged
68 years. There was no significant heterogeneity among trials. Additional
nalysis did not reveal any modifying effects mediated by symptomatic or
symptomatic status, distal protection devices, early termination of trials, area of
tudy origin, or CAS learning curve.
Comment: The frequently reported advantages of CEA over CAS in
reventing short-term risk of stroke are now reported to be continued in the
ong-term. There are, of course, still many questions regarding the use of CEA
rCAS.Wedonot knowwhich is better in patientswith acute stroke, nor dowe
now about long-term restenosis. Overall, CEA and CAS may be roughly
quivalent with regard to neurologic outcome in younger patients; however, if
he overall goal is to prevent stroke, CEA is more effective than CAS.
holesterol Efflux Capacity, High-Density Lipoprotein Function, and
therosclerosis
hera AV, Cuchel M, de la Llera-moya M, et al. N Engl J Med 2011;364:
27-35.
Conclusion: Cholesterol efflux capacity has a strong inverse relation-
hip with angiographic coronary artery disease and carotid intima-media
hickness independent of high-density lipoprotein (HDL) cholesterol level.
Summary: A strong inverse association exists between levels of HDL
holesterol and cardiovascular disease risk. Pharmacologic increases in HDL
holesterol have thus been postulated to reduce cardiovascular risk. How-
ver, an inhibitor of cholesteryl ester transfer protein (CETP) was found to
esult in a 72% increase in HDL cholesterol levels, but was associated with an
ncrease in the number of cardiovascular events (Barter PJ [N Engl J Med
007;357:2109-22]). This may be because HDL has marked heterogeneity
n particle composition that affects its biologic properties. Emphasis has
herefore shifted on not only measurement of HDL cholesterol levels but on
he development of a validated measure of HDL function (Vaisar T [J Clin
nvest 2007;117:746-56]). There may be many components of HDL-
ediated atheroprotection. The ability of HDL to promote reverse choles-
erol transport by accepting cholesterol from lipid-laden macrophages may
e important. This is termed “cholesterol efflux capacity” (Tall AR [J Intern
ed 2008;263:256-73]).
